← Back to Clinical Trials
Recruiting NCT06059352

NCT06059352 Sleep and Central Auditory Processing Disorder in Autism Spectrum Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06059352
Status Recruiting
Phase
Sponsor Loma Linda University
Condition Central Auditory Processing Disorder
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-11-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 17 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-11-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The proposed study aims to understand poor sleep as a possible cause to CAPD in children and adolescents with ASD (ASD+) compared to ASD youth without CAPD (ASD-), using both caregiver-report and objective clinician administered measures. Additionally, the study will aim to understand the complex relationship between CAPD, sleep, and other associated phenotypic features of ASD such as executive and psychiatric functioning.

Eligibility Criteria

Inclusion Criteria: * Have diagnosis of Autism Spectrum Disorder confirmed by the Autism Diagnostic Observation Schedule and the Social Communication Questionnaire, Lifetime Version which will be filled by the parent * IQ of 50 or higher on the Abbreviated Battery IQ Score Exclusion Criteria: * No confirmed diagnosis of Autism Spectrum Disorder * History of sleep apnea * History of restless leg syndrome * History of any neurological disorders (e.g., seizures, tumors, etc.) * Significant substance use in the past six months * Inpatient hospitalization in the past three months-period

Contact & Investigator

Central Contact

Fatimah Alramadhan, DrPH

✉ falramadhan@llu.edu

📞 9095584000

Principal Investigator

Aarti Nair, PhD

PRINCIPAL INVESTIGATOR

Loma Linda University

Frequently Asked Questions

Who can join the NCT06059352 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Central Auditory Processing Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06059352 currently recruiting?

Yes, NCT06059352 is actively recruiting participants. Contact the research team at falramadhan@llu.edu for enrollment information.

Where is the NCT06059352 trial being conducted?

This trial is being conducted at Loma Linda, United States.

Who is sponsoring the NCT06059352 clinical trial?

NCT06059352 is sponsored by Loma Linda University. The principal investigator is Aarti Nair, PhD at Loma Linda University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology